2007 could be a pivotal year, bringing new technologies and
positive clinical developments for therapeutic cancer
vaccine products.


New technologies include DNA and cellular delivery, TLR
receptor agonists, and adjuvants.

Recent News is that five well-funded public companies with
proprietary technology and late-stage trials utilizing
active immunotherapy along with combination therapy to
complement antibody treatment and chemotherapy.

One of the method namely "Dendrion" is to use a selected
cancer?related target protein to stimulate a patient?s own
dendritic cells, which are then reinfused into the patient
to stimulate an immune response.

Dendreon also completed a Phase I evaluation of Neuvenge, an
investigative active cellular immunotherapy for the
treatment of breast, ovarian, and colon cancers.